Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, Sekine M, Akizuki K, Shimoda H, Yamaji T, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A. Shimoda K, et al. Among authors: shimoda h. J Clin Exp Hematop. 2015;55(3):145-9. doi: 10.3960/jslrt.55.145. J Clin Exp Hematop. 2015. PMID: 26763362 Free article.
TET2 mutation in diffuse large B-cell lymphoma.
Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: shimoda h, shimoda k. J Clin Exp Hematop. 2017;56(3):145-149. doi: 10.3960/jslrt.56.145. J Clin Exp Hematop. 2017. PMID: 28331128 Free PMC article.
TET2 is essential for survival and hematopoietic stem cell homeostasis.
Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K. Shide K, et al. Among authors: shimoda h, shimoda k. Leukemia. 2012 Oct;26(10):2216-23. doi: 10.1038/leu.2012.94. Epub 2012 Apr 3. Leukemia. 2012. PMID: 22469782
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: shimoda h, shimoda k. Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13. Blood. 2015. PMID: 25395421 Free article.
Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, Maeda K, Sato S, Ishizaki J, Kawano H, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Shide K, Hidaka T, Kitanaka A, Yamashita K, Matsuoka H, Shimoda K. Sekine M, et al. Among authors: shimoda h, shimoda k. Eur J Haematol. 2017 May;98(5):501-507. doi: 10.1111/ejh.12863. Epub 2017 Mar 10. Eur J Haematol. 2017. PMID: 28152225
Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
Kameda T, Shide K, Tahira Y, Sekine M, Sato S, Ishizaki J, Takeuchi M, Akizuki K, Kamiunten A, Shimoda H, Toyama T, Maeda K, Yamashita K, Kawano N, Kawano H, Hidaka T, Yamaguchi H, Kubuki Y, Kitanaka A, Matsuoka H, Shimoda K. Kameda T, et al. Among authors: shimoda h, shimoda k. Viruses. 2022 Mar 29;14(4):710. doi: 10.3390/v14040710. Viruses. 2022. PMID: 35458440 Free PMC article.
Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K, Taniguchi Y, Sekine M, Kamiunntenn A, Maeda K, Nagata K, Matsunaga T, Shimoda K. Kameda T, et al. Among authors: shimoda hk, shimoda k. Int J Hematol. 2010 Sep;92(2):320-5. doi: 10.1007/s12185-010-0653-2. Epub 2010 Aug 10. Int J Hematol. 2010. PMID: 20697856
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
Sekine M, Kameda T, Shide K, Maeda K, Toyama T, Kawano N, Takeuchi M, Kawano H, Sato S, Ishizaki J, Kukita T, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Hidaka T, Yamashita K, Matsuoka H, Kitanaka A, Kubuki Y, Shimoda K. Sekine M, et al. Among authors: shimoda h, shimoda k. Eur J Haematol. 2021 Mar;106(3):398-407. doi: 10.1111/ejh.13565. Epub 2020 Dec 19. Eur J Haematol. 2021. PMID: 33301622
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K. Shide K, et al. Among authors: shimoda h, shimoda k. Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3. Leukemia. 2017. PMID: 27807369 Free PMC article.
348 results